Data a 'Milestone' Against Fatal Illness
Sarepta Therapeutics announced its eteplirsen compound achieved significant clinical benefit in the potential treatment of Duchenne muscular dystrophy. One researched called it a "significant milestone" in the treatment of a disease that's confounded the medical community for decades. SRPT explodes higher by 115 percent before the bell on my tradeMONSTER platform!
Xryatex Falls on Earnings Miss, Weak Guidance
Xryatex reported third-quarter earnings of $0.37 a share on revenue of $275.7 million. That's well below the consensus estimates for profit of $0.44 and revenue of $316.3 million. Management also issued weak guidance as demand from enterprise customers fell. XRTX craters 11 percent in early trading.
Canadian Approval Lifts InterMune
InterMune announced that Canadian health regulators approved marketing of its Esbriet drug for the treatment of the lung disease idiopathic pulmonary fibrosis. ITMN surges 11 percent in the premarket.
More From optionMONSTER
- Momentum remains positive for stocks
- Bulls won't hang up on Sprint Nextel
- Trader bucks fear in Brazilian lender
- Duchenne muscular dystrophy